
News|Articles|January 29, 2024
Alternative buffer management strategies to achieve downstream process improvements
Author(s)Avantor
Buffers are used in great quantities when producing monoclonal antibodies (mAbs), and many biopharmaceutical companies — even large ones — do not have the processing capacity or infrastructure in-house to handle these large volumes. Whether it’s providing quality, pre-weighed, GMP-compliant raw materials or the entire buffer preparation step, there are options available to optimize your process.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Trending on Pharmaceutical Technology
1
Drug Digest: Outsourcing Partnerships Fuel Global Biopharma Discovery and Scale-Up
2
Women in STEM: Early Phase Drug Development
3
FDA Grants Priority Review For Pfizer’s Marstacimab for Hemophilia A or B
4
PharmTech Weekly Roundup - February 6, 2026
5